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The QRS duration has been well established as a predictor of mortality in patients 
with heart failure with reduced ejection fraction [1]. In patients with heart failure with 
preserved ejection fraction (HFpEF), some studies have shown that prolonged QRS duration 
has been associated with increased morbidity and mortality [2, 3]. However, these studies 
were based mainly on Western cohorts with scarce data from Asia, where normal ranges for 
QRS duration may differ [4, 5]. The aim of this study   was to examine the association 
between QRS duration and mortality in an Asian heart failure cohort. 
Consecutive patients who were admitted with heart failure as the primary diagnosis 
from two institutions from 1 January 2008 to 31 December 2009 were included. Those with 
paced rhythms were excluded. The QRS interval was measured by trained staff on a 12-lead 
electrocardiogram upon admission. HFpEF was defined as heart failure patients with EF ≥ 
50% and ≥ grade 1 diastolic dysfunction on the echocardiogram or N-terminal-pro-B-type 
natriuretic peptide (NT-proBNP) level > 220 pg/mL heart failure with non-preserved EF 
(HFnpEF) was defined as EF < 50%. The outcomes were obtained from national registries. 
All patients were followed-up till December 2014. The primary outcomes were all-cause 
mortality and cardiovascular mortality. Ethics approval was obtained from the institutional 
review board.  
Cox proportional hazard modelling was used to identify predictors of all-cause and 
cardiovascular mortality. Variables significant on univariate analysis (p < 0.05) were selected 
for the multivariate models. Multivariate Cox proportional hazard models were then 
performed for each heart failure cohort to calculate hazard ratios (HR) and associated 95% 
confidence intervals (CI) for mortality. QRS duration was analyzed both as a continuous and 
categorical variable. The optimal QRS cut-off was assessed by area under receiver operating 
characteristics (AUROC) curve. Data was analyzed using the Statistical Package for the 
Social Sciences (SPSS®, version 23.0). A p value of < 0.05 was taken to be statistically 
significant.  
A total of 666 HFpEF (mean age 73.1 ± 10.5, 36.3% male, mean LVEF 61 ± 8%) and 
1032 HFnpEF (mean age 66.3 ± 12.4 years, 64.3% male, mean LVEF 29 ± 13%) were 
included. The clinical characteristics are summarized in Table 1.  
In patients with HFpEF, 5-year overall and cardiovascular mortality was 57% (n = 
381) and 28% (n = 189) respectively. QRS duration as a continuous variable was a significant 
predictor of cardiovascular (adjusted HR 1.010; 95% CI 1.002–1.018; p = 0.011) but not 
overall mortality (p = 0.190). A cut-off of 100ms was found to provide the optimal 
discriminatory AUC compared to other cut-offs including 90 ms, 110 ms and 120 ms. A QRS 
≥ 100 ms was a significant predictor of cardiovascular mortality (adjusted HR 1.468; 95% CI 
1.014–2.126; p = 0.042) but not overall mortality (adjusted HR 1.287; 95% CI 0.993–1.668; 
p = 0.056). 
In patients with HFnpEF, 5-year overall and cardiovascular mortality was 65% (n = 
673) and 43.0% (n = 444). QRS duration as a continuous variable was a significant predictor 
of both overall (adjusted HR 1.005; 95% CI 1.001–1.008; p = 0.004) and cardiovascular 
mortality (adjusted HR 1.006; 95% CI 1.002–1.010; p = 0.003). A cut-off of 100 ms was 
found to provide the optimal discriminatory AUC compared to other cut-offs including 90 
ms, 110 ms and 120 ms. QRS ≥ 100 ms was a significant predictor of both overall (adjusted 
HR 1.262; 95% CI 1.047–1.522; p = 0.015) and cardiovascular mortality (adjusted HR 1.336; 
95% CI 1.058–1.688; p = 0.015; Table 2). 
In this Asian HFnpEF cohort, it was found that QRS prolongation predicted both 
overall and cardiovascular mortality. This is in-line with current literature [1] and lends 
further evidence to the detrimental impact of QRS prolongation across different ethnicities.  
Of greater interest are the results from the HFpEF cohort. In two non-Asian studies, 
QRS prolongation in HFpEF impacted upon overall mortality [2, 3]. In one of the few Asian 
studies to-date, Gisberts found a significant association of QRS duration on overall mortality 
in heart failure with reduced ejection fraction patients, but not in HFpEF patients [4]; 
cardiovascular mortality was not assessed. The neutral all-cause mortality finding was similar 
to that of our HFpEF cohort. However,  a significant relationship with cardiovascular 
mortality was additionally found in the HFpEF patients of the current study. This is 
pathophysiologically plausible with QRS prolongation indicative of cardiac abnormalities [7]. 
Of note, the cut-offs in the above two non-Asian studies was found to be 120 ms [2, 3]; a cut-
off of 100 ms to was found have greater discriminatory value in the Asian cohort. This may 
be a result of body size or ethnicity [4, 5]. It was found that the average QRS duration in a 
healthy community-based cohort of Chinese, Malays and Indians was 89 ms in males and 83 
ms in female [5]. In the Framingham heart study, the average QRS duration in a healthy 
Caucasian male was 97 ms and 87 ms in females [8]. Several studies have shown that 
increasing body size results in increasing QRS duration [5] and this may account for the 
lower QRS cut-offs as seen in the present study with known smaller body sizes of Asians. 
The differences in findings between the current HFpEF and HFnpEF cohort are likely the 
result of both conditions being separate disease entities. Multiple studies have previously 
shown distinct clinical and prognostic differences between these groups [6]. 
HFpEF remains a difficult clinical condition to manage due to its limited therapeutic 
options. Risk stratification is challenging and has fewer established prognostic markers [9]. 
An electrocardiogram is readily available and thus QRS duration could potentially be used as 
a simple risk stratification tool for clinicians. QRS prolongation has been linked to 
mechanical desynchrony in HFpEF [10]. In appropriate heart failure with reduced ejection 
fraction patients, the use of cardiac resynchronisation therapy has been shown to provide 
mortality and symptomatic benefit, but how this eventually translates to therapeutic options 
for HFpEF is less clear. Regardless, HFpEF patients with prolonged QRS duration identifies 
a subset at higher risk of adverse outcomes; greater efforts must be taken to optimise the 
holistic care of these patients including control of cardiovascular risk factors. 
Limitations of the present study include primary use of hospitalised patients with 
heart failure; more stable patients in an outpatient/community setting may have been 
different. Secondly, the current cohort consisted of patients who were mainly of Chinese, 
Malay and Indian ethnicity which reflects the population distribution in Singapore; the data 
should be validated in other Asian ethnicities. Thirdly, the uptake of guideline directed 
medical therapy in the present cohort reflects real-world practice and this cohort was 
recruited from 2008 to 2009; the potential impact of heart failure therapies, especially the 
more contemporary medications, will be the work of future studies. Lastly, the QRS duration 
was only available from the admission electrocardiogram. Changes in QRS duration over 
time was not captured. 
In the present Asian heart failure cohort, QRS duration is a significant predictor of 
cardiovascular mortality in both HFpEF and HFnpEF patients. QRS duration also 
significantly predicted overall mortality in HFnpEF patients.  
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Table 1. Clinical characteristics of the study population. 
 Preserved ejection fraction (n = 666) Reduced ejection fraction (n = 1032) 
 < 100 ms (n 
= 482) 
≥ 100 ms (n 
= 184) 
P < 100 ms (n = 
484) 
≥ 100 ms (n = 
548) 
P 
Demographics 
Mean age (SD) 73.0 (10.5) 72.6 (11.0) 0.634 65.9 (12.8) 66.8 (12.1) 0.239 
Male 141 (29.3%) 101 (54.9%) < 0.001 272 (56.2%) 394 (71.9%) < 0.001 
Race:       
Chinese 360 (74.7%) 136 (73.9%) 0.452 328 (67.8%) 372 (67.9%) 0.545 
Malay 55 (11.4%) 24 (13.0%)  95 (19.6%) 94 (17.2%)  
Indian 59 (12.2%) 18 (9.8%)  51 (10.5%) 71 (13.0%)  
Others 8 (1.7%) 6 (3.3%)  10 (2.1%) 11 (2.0%)  
       
Clinical characteristics 
Prior CAD  204 (42.3%) 69 (37.5%) 0.258 193 (39.9%) 298 (54.4%) < 0.001 
Prior MI  80 (16.6%) 34 (18.5%) 0.564 179 (37.0%) 210 (38.3%) 0.658 
Atrial fibrillation 164 (34.0%) 73 (39.7%) 0.173 94 (19.4%) 127 (23.2%) 0.142 
Diabetes mellitus 225 (46.7%) 86 (46.7%) 0.989 304 (62.8%) 277 (50.5%) <0.001 
Hypertension 388 (80.5%) 139 (75.5%) 0.159 324 (66.9%) 386 (70.4%) 0.226 
Hyperlipidemia 297 (61.6%) 96 (52.2%) 0.027 306 (63.2%) 355 (64.8%) 0.603 
Stroke 86 (17.8%) 36 (19.6%) 0.607 66 (13.6%) 78 (14.2%) 0.782 
PVD  24 (5.0%) 12 (6.5%) 0.431 35 (7.2%) 38 (6.9%) 0.853 
COPD  61 (12.7%) 30 (16.3%) 0.220 48 (9.9%) 74 (13.5%) 0.075 
Ever smoker 116 (24.1%) 67 (36.4%) 0.001 202 (41.7%) 279 (50.9%) 0.003 
Systolic BP (SD) 
[mmHg] 
143.1 (29.1) 140.3 (31.3) 0.266 139.8 (30.5) 133.6 (29.2) 0.001 
Diastolic BP (SD) 
[mmHg] 
73.2 (16.5) 72.4 (17.5) 0.608 80.6 (19.3) 75.6 (18.3) <0.001 
Heart rate (SD) 84.4 (22.9) 78.8 (22.9) 0.005 92.8 (21.0) 84.4 (18.3) <0.001 
QRS duration (SD) 85.1 (8.1) 115.7 (17.5) <0.001 87.9 (7.6) 123.9 (24.2) <0.001 
NT-proBNP (SD) 
[pg/mL] 
5079.9 
(7141.8) 
8282.3 
(11909.7) 
0.061 11741.1 
(14600.0) 
12389.6 
(15358.1) 
0.537 
Creatinine (SD) 
[μmol/L] 
121.4 (84.8) 145.9 (125.3) 0.015 133.4 (98.4) 141.2 (92.7) 0.186 
Sodium (SD) [mmol/L] 136.4 (4.9) 136.2 (5.2) 0.706 136.0 (7.3) 135.8 (8.7) 0.713 
Potassium (SD) 
[mmol/L] 
4.2 (0.8) 4.2 (0.8) 0.451 4.3 (0.8) 4.3 (1.8) 0.895 
Hemoglobin (SD) 
[g/dL] 
11.7 (2.0) 12.0 (2.1) 0.085 12.4 (2.1) 12.6 (2.0) 0.046 
Discharge medications 
ACEI/ARB  284 (58.9%) 114 (62.0%) 0.475 360 (74.4%) 415 (75.7%) 0.617 
Beta-blocker 240 (49.8%) 98 (53.3%) 0.423 314 (64.9%) 369 (67.3%) 0.405 
Spironolactone/Aldoste
rone antagonist 
35 (7.3%) 17 (9.2%) 0.395 90 (18.6%) 145 (26.5%) 0.003 
Nitrate 192 (39.8%) 84 (45.7%) 0.173 245 (50.6%) 312 (56.9%) 0.042 
Diuretic  365 (75.7%) 148 (80.4%) 0.176 424 (87.6%) 476 (86.9%) 0.722 
Digoxin 88 (18.3%) 37 (20.1%) 0.584 130 (26.9%) 158 (28.8%) 0.481 
ASA 196 (40.7%) 87 (47.3%) 0.122 282 (58.3%) 331 (60.4%) 0.485 
Clopidogrel 63 (13.1%) 16 (8.7%) 0.118 89 (18.4%) 90 (16.4%) 0.405 
Warfarin 86 (17.8%) 33 (17.9%) 0.978 52 (10.7%) 70 (12.8%) 0.313 
Lipid-lowering 301 (62.4%) 112 (60.9%) 0.707 357 (73.8%) 395 (72.1%) 0.545 
CAD — coronary artery disease; MI — myocardial infarction; PVD — peripheral vascular disease; COPD — chronic 
obstructive pulmonary disease; BP — blood pressure; NT-proBNP — N-terminal-pro-B-type natriuretic peptide; ACEI/ARB 
— angiotensin converting enzyme/angiotensin receptor blocker; ASA — acetylsalicylic acid 
 
 
Table 2. QRS duration,all-cause and cardiovascular mortality. 
 Unadjusted 
overall mortality 
Unadjusted CVS 
mortality 
Adjusted overall 
mortality 
Adjusted CVS 
mortality 
 HR (95% 
CI) 
P  HR (95% 
CI) 
P  HR (95% 
CI) 
P  HR (95% 
CI) 
P  
Preserved ejection fraction 
QRS duration 
(continuous) 
1.007 
(1.002–
1.013) 
0.012 1.013 
(1.006–
1.020) 
< 
0.001 
1.004 
(0.998–
1.011) 
0.190* 1.010 
(1.002–
1.018) 
0.011** 
QRS duration 
(categorical) 
        
< 100 ms         
≥100 ms  1.347 
(1.086–
1.671) 
0.007 1.674 
(1.246–
2.250) 
0.001 1.287 
(0.993–
1.668) 
0.056* 1.468 
(1.014–
2.126) 
0.042** 
Reduced ejection fraction 
QRS duration 
(continuous) 
1.005 
(1.002–
1.007) 
0.001 1.007 
(1.004–
1.010) 
< 
0.001 
1.005 
(1.001–
1.008) 
0.004^ 1.006 
(1.002–
1.010) 
0.003^^ 
QRS duration 
(categorical) 
        
< 100 ms         
≥ 100 ms  1.249 
(1.072–
1.454) 
0.004 1.488 
(1.230–
1.800) 
< 
0.001 
1.262 
(1.047–
1.522) 
0.015^ 1.336 
(1.058–
1.688) 
0.015^^ 
HR — hazard ratio; CI — confidence interval; other abbreviations — see Table 1 
*Adjusted for age, gender, left ventricular hypertrophy, prior MI, atrial fibrillation, stroke, PVD, smoker, 
diastolic BP, NT-proBNP, creatinine, sodium, potassium, hemoglobin, ACEI/ARB, beta-blocker, warfarin  
**Adjusted for age, ethnicity, left bundle branch block, left ventricular hypertrophy, prior MI, hyperlipidemia, 
stroke, PVD, systolic BP, NT-proBNP, creatinine, potassium, haemoglobin, warfarin 
^Adjusted for age, heart rate, coronary artery disease, prior MI, atrial fibrillation, diabetes mellitus, 
hypertension, hyperlipidaemia, stroke, PVD, systolic BP, diastolic BP, NT-proBNP, creatinine, hemoglobin, 
ACEI/ARB use, beta-blocker use, nitrates use, ASA use 
^^Adjusted for age, heart rate, right ventricular hypertrophy, CAD, prior MI, atrial fibrillation, diabetes mellitus, 
hyperlipidemia, stroke, PVD, systolic BP, diastolic BP, NT-proBNP, creatinine, hemoglobin, ACEI/ARB, 
aldosterone antagonist 
 
